DK3097189T3 - Kimæriske alkalisk phosphatase-lignende proteiner - Google Patents
Kimæriske alkalisk phosphatase-lignende proteiner Download PDFInfo
- Publication number
- DK3097189T3 DK3097189T3 DK15703642.7T DK15703642T DK3097189T3 DK 3097189 T3 DK3097189 T3 DK 3097189T3 DK 15703642 T DK15703642 T DK 15703642T DK 3097189 T3 DK3097189 T3 DK 3097189T3
- Authority
- DK
- Denmark
- Prior art keywords
- recap
- lvl
- protein
- disease
- amino acid
- Prior art date
Links
- 0 CCC(C*(C(C(*)C1O)O)N)C1(C(*)C(C(C(*C)*C(C*C(*)CCC(C)*)O)O)O)N Chemical compound CCC(C*(C(C(*)C1O)O)N)C1(C(*)C(C(C(*C)*C(C*C(*)CCC(C)*)O)O)O)N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03001—Alkaline phosphatase (3.1.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
Claims (15)
1. Isoleret protein med alkalisk phosphataseaktivitet, hvor proteinet omfatter en aminosyresekvens af 365 konsekutive aminosyrer med mindst 98 % sekvensidentitet med SEQ ID NO: 5 som anført i Figur 1, en aminosyresekvens af 65 konsekutive aminosyrer med mindst 98 % sekvensidentitet med SEQ ID NO: 6 som anført i Figur 1 og en aminosyresekvens af 54 konsekutive aminosyrer med mindst 98 % sekvensidentitet med SEQ ID NO: 7 som anført i Figur 1, hvor fuldlængdeproteinet omfatter en aminosyresekvens med mindst 98 % sekvensidentitet med fuldlængdeaminosyresekvensen ifølge SEQ ID NO: 1 som anført i Figur 1. forudsat at aminosyren ved position 279 er leucin (L), aminosyren ved position 328 er valin (V) og aminosyren ved position 478 er leucin (L).
2. Polynukleotid, der omfatter en nukleinsyresekvens, der koder for et protein ifølge krav 1.
3. Vektor, der omfatter et polynukleotid ifølge krav 2.
4. Protein ifølge krav 1, polynukleotid ifølge krav 2 eller vektor ifølge krav 3 til anvendelse som et lægemiddel.
5. Protein, polynukleotid eller vektor til anvendelse ifølge krav 4 til anvendelse i en fremgangsmåde til forebyggelse eller behandling af en inflammatorisk sygdom, en nyresygdom eller hypofosfatasi.
6. Protein, polynukleotid eller vektor til anvendelse ifølge krav 5, hvor den inflammatoriske sygdom er valgt fra gruppen af autoimmune sygdomme, rheumatoid arthritis, astma, kronisk obstruktiv lungesygdom, aterosklerose, inflammatorisk sygdom i mavetarmkanalen, infektion, sepsis, neurodermatitis, inflammatorisk liver sygdom, inflammatorisk lungesygdom og inflammatorisk nyresygdom.
7. Protein, polynukleotid eller vektor til anvendelse ifølge krav 5, hvor nyresygdommen er valgt fra gruppen af nyrelæsion, akut nyrelæsion, kronisk nyresygdom, nyresvigt, akut nyresvigt, iskæmisk nyresygdom og iskæmi/reperfusionsnyreskade.
8. Protein, polynukleotid eller vektor til anvendelse ifølge krav 5, hvor hypofosfatasien er valgt fra gruppen af perinatal hypofosfatasi, infantil hypofosfatasi, hypofosfatasi hos børn og hypofosfatasi hos voksne.
9. Værtscelle, der omfatter et protein ifølge krav 1, et polynukleotid ifølge krav 2 eller en vektor ifølge krav 3.
10. Værtscelle ifølge krav 9, hvor værtscellen er en CHO-celle.
11. Fremgangsmåde til fremstilling af et protein ifølge krav 1, der omfatter dyrkning af værtscellen ifølge krav 9 eller 10 og at lade værtscellen producere proteinet.
12. Sammensætning, der omfatter et protein ifølge krav 1, og/eller som kan opnås ved en fremgangsmåde ifølge krav 11.
13. Sammensætning ifølge krav 12 til anvendelse som et lægemiddel.
14. Sammensætning til anvendelse ifølge krav 13, hvor lægemidlet er beregnet til anvendelse i forebyggelse eller behandling af en inflammatorisk sygdom, en nyresygdom eller hypofosfatasi.
15. Protein, polynukleotid eller vektor til anvendelse ifølge krav 5 eller 8 eller en sammensætning til anvendelse ifølge krav 14, hvor forebyggelsen eller behandlingen af hypofosfatasi resulterer i forlænget overlevelse, øget kropsvægt, forbedre skeletfænotype, dæmpning af kraniofaciale defekter, bedring af dentoalveolær fænotype og/eller reduktion af plasma-PPi-niveauer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14152526 | 2014-01-24 | ||
| EP14188158 | 2014-10-08 | ||
| PCT/NL2015/050048 WO2015112017A1 (en) | 2014-01-24 | 2015-01-26 | Chimeric alkaline phosphatase-like proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3097189T3 true DK3097189T3 (da) | 2018-09-03 |
Family
ID=52464544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15703642.7T DK3097189T3 (da) | 2014-01-24 | 2015-01-26 | Kimæriske alkalisk phosphatase-lignende proteiner |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9926544B2 (da) |
| EP (2) | EP3097189B1 (da) |
| JP (3) | JP6940949B2 (da) |
| KR (1) | KR102166110B1 (da) |
| CN (2) | CN106164262B (da) |
| AU (1) | AU2015209783B2 (da) |
| BR (1) | BR112016017041B1 (da) |
| CA (1) | CA2937328C (da) |
| DK (1) | DK3097189T3 (da) |
| ES (1) | ES2684639T3 (da) |
| HU (1) | HUE039784T2 (da) |
| IL (1) | IL246898B (da) |
| MX (1) | MX369041B (da) |
| PE (1) | PE20161442A1 (da) |
| PH (1) | PH12016501441B1 (da) |
| PL (1) | PL3097189T3 (da) |
| RU (1) | RU2683635C2 (da) |
| SA (1) | SA516371532B1 (da) |
| SG (1) | SG11201606060WA (da) |
| SI (1) | SI3097189T1 (da) |
| WO (1) | WO2015112017A1 (da) |
| ZA (1) | ZA201605028B (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2937328C (en) | 2014-01-24 | 2022-09-27 | Am-Pharma B.V. | Chimeric alkaline phosphatase-like proteins |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| MX389350B (es) | 2014-12-05 | 2025-03-19 | Alexion Pharma Inc | Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones. |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| CN108350440A (zh) * | 2015-08-17 | 2018-07-31 | 阿雷克森制药公司 | 碱性磷酸酯的制造 |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| JP7613826B2 (ja) | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3345614A1 (en) * | 2017-01-05 | 2018-07-11 | Amrif B.V. | Composition comprising alkaline phosphatase for use in the treatment of arthritides |
| EP3600383A4 (en) * | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS |
| US11338020B2 (en) * | 2018-01-09 | 2022-05-24 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
| FI3762018T3 (fi) * | 2018-03-08 | 2024-04-22 | Am Pharma Bv | Rekombinantti alkalinen fosfataasi käytettäväksi sepsikseen liittyvän akuutin munuaisvaurion hoitamiseen |
| ES3032290T3 (en) | 2018-03-20 | 2025-07-16 | Theriva Biologics Inc | Intestinal alkaline phosphatase formulations |
| US11654184B2 (en) | 2018-03-20 | 2023-05-23 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| CN110499285A (zh) * | 2018-05-17 | 2019-11-26 | 西安组织工程与再生医学研究所 | Alpl基因在制备预防和/或治疗低碱性磷酸酶症的产品中的应用 |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| JP7660523B2 (ja) | 2019-05-06 | 2025-04-11 | セリバ・バイオロジクス・インコーポレイテッド | アルカリリン酸塩に基づいた癌治療 |
| CA3161266A1 (en) | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| JP7813706B2 (ja) * | 2020-01-03 | 2026-02-13 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 歯周の健康を促進するために局所投与されるｔｎａｐ |
| CN111110835A (zh) * | 2020-01-22 | 2020-05-08 | 李鑫荣 | 一种肠碱性磷酸酶的新应用及其制剂的细胞活性检测方法 |
| AU2021337652B2 (en) | 2020-09-04 | 2025-01-30 | Alexion Pharmaceuticals, Inc. | Methods for treating bone mineralization disorders |
| WO2022055350A1 (en) | 2020-09-09 | 2022-03-17 | Am-Pharma B.V. | Recombinant alkaline phosphatase for use in treating acute respiratory distress syndrome |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
| CN118580341B (zh) * | 2024-06-24 | 2025-03-18 | 浙江大学 | 一种寄生线虫spi-i8蛋白及其在防治炎症疾病中的应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8328918D0 (en) | 1983-10-28 | 1983-11-30 | Unilever Plc | Alkaline phosphatase |
| ES2106737T3 (es) | 1990-02-07 | 1997-11-16 | Abbott Lab | Enzimas de fosfatasa alcalina con actividad especifica mejorada para uso en reactivos indicadores. |
| EP0584343B1 (en) | 1992-03-10 | 1999-01-20 | La Jolla Cancer Research Foundation | Recombinant calf intestinal alkaline phosphatase |
| JPH06284885A (ja) * | 1993-04-02 | 1994-10-11 | Tosoh Corp | 組換えヒト小腸アルカリフォスファタ−ゼ |
| EP0701441A1 (en) | 1993-06-01 | 1996-03-20 | Cortex Pharmaceuticals, Inc. | Alkaline and acid phosphatase inhibitors in treatment of neurological disorders |
| WO1995005455A1 (en) | 1993-08-13 | 1995-02-23 | Rijksuniversiteit Te Groningen | Pharmaceutical composition comprising phosphatase or a derivative thereof |
| CA2176709A1 (en) | 1993-11-15 | 1995-05-26 | Howard R. Higley | Method of treating renal disease by administering igf-i and igfbp-3 |
| MXPA97009909A (es) | 1995-06-06 | 2004-08-23 | Gensci Regeneration Lab Inc | Materiales osteogenicos modificados. |
| FR2736065B1 (fr) | 1995-06-29 | 1997-09-19 | Commissariat Energie Atomique | Phosphatases alcalines bacteriennes modifiees et leurs applications. |
| JP3488327B2 (ja) | 1995-12-21 | 2004-01-19 | よつ葉乳業株式会社 | 牛乳脂肪球膜含有画分の製造法 |
| US20020114802A1 (en) | 1998-02-10 | 2002-08-22 | Tjellstrom Bo Arthur Einar | Oral immunoglobulin treatment for inflammatory bowel disease |
| DE19819962A1 (de) | 1998-05-05 | 1999-11-11 | Roche Diagnostics Gmbh | Hochaktive alkalische Phosphatase |
| JP2002533679A (ja) | 1998-12-21 | 2002-10-08 | フアーマアウエア・アイピー・ベー・ブイ | アルカリホスファターゼのｌｐｓ−結合部分を使用する敗血症の診断 |
| JP2000350596A (ja) | 1999-06-11 | 2000-12-19 | Toyobo Co Ltd | 分泌性アルカリフォスファターゼの選択的活性測定方法 |
| DE60120007T2 (de) | 2000-01-31 | 2006-11-16 | Pfizer Products Inc., Groton | Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz |
| DE60129442T2 (de) | 2000-07-19 | 2008-04-17 | Mitsubishi Pharma Corp. | Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten |
| EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| DE10101793A1 (de) | 2001-01-17 | 2002-08-01 | Manfred Nilius | Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen |
| WO2002057430A2 (en) | 2001-01-20 | 2002-07-25 | Cardion Ag | Pluripotent adult stem cells derived from regenerative tissue |
| EP1393734A4 (en) | 2001-06-01 | 2006-04-12 | Ajinomoto Kk | DRUG AGAINST DARMER DISEASES |
| US7157260B2 (en) | 2001-07-26 | 2007-01-02 | Japan Science & Technology Agency | Nicotianamine synthase and gene encoding the same |
| JP4169966B2 (ja) | 2001-11-14 | 2008-10-22 | 株式会社ヤクルト本社 | 炎症性腸疾患予防治療剤 |
| CN1425766A (zh) | 2001-12-19 | 2003-06-25 | 复旦大学 | 一种多肽——人含碱性磷酸酶活性位点的蛋白－9.24和编码这种多肽的多核苷酸 |
| EP1578940A4 (en) * | 2002-11-13 | 2007-12-12 | Genentech Inc | METHOD AND COMPOSITIONS FOR DYSPLASED DIAGNOSIS |
| US7048914B2 (en) | 2002-12-12 | 2006-05-23 | Zoltan Laboratories | Placental alkaline phosphatase to control diabetes |
| WO2004056987A1 (en) * | 2002-12-23 | 2004-07-08 | Rijksuniversiteit Groningen | Modulation of the thioredoxin pathway |
| AU2003225410A1 (en) | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| JP4305071B2 (ja) | 2003-06-30 | 2009-07-29 | 株式会社ニコン | 信号補正方法 |
| JP2005065564A (ja) | 2003-08-22 | 2005-03-17 | Hiroshi Ueda | センサー蛋白質 |
| US7157261B2 (en) | 2003-10-27 | 2007-01-02 | Canji, Inc. | Rat secreted embryonic alkaline phosphatase |
| JP4999467B2 (ja) | 2004-02-04 | 2012-08-15 | ファルマアウェア セプシス ビー．ブイ． | 粘膜関門に存在するｌｐｓを解毒するためのアルカリホスファターゼの使用 |
| US20110142817A1 (en) | 2004-02-04 | 2011-06-16 | Pharmaaware Sepsis B.V. | Means and method for treating and/or preventing necrotizing enterocolitis |
| WO2006096527A2 (en) | 2005-03-04 | 2006-09-14 | Diversa Corporation | Nucleic acids and proteins and methods for making and using them |
| US20070059300A1 (en) | 2005-09-12 | 2007-03-15 | Zoltan Laboratories Llc | Compounds and compositions to control abnormal cell growth |
| US7695714B2 (en) | 2005-12-28 | 2010-04-13 | Zoltan Laboratories Llc | Use of alkaline phosphatase to maintain healthy tissue mass in mammals |
| RU2006103770A (ru) * | 2006-02-08 | 2007-08-20 | Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) (Ru) | Высокоактивная бактериальная щелочная фосфатаза и фрагмент днк, кодирующий щелочную фосфатазу |
| US20070280922A1 (en) | 2006-06-06 | 2007-12-06 | Zoltan Kiss Consulting | Combinations of human proteins to enhance viability of stem cells and progenitor cells |
| US7718170B2 (en) | 2006-08-21 | 2010-05-18 | Essential Skincare, Llc | Alkaline phosphatase compositions to reduce skin cancer |
| EP1952823A1 (en) | 2007-01-30 | 2008-08-06 | AM-Pharma B.V. | The use of alkaline phosphatase in the treatment of reduced renal function |
| WO2008104199A1 (en) | 2007-03-01 | 2008-09-04 | Gelato Corporation N.V. | Use of ecto-phosphatases for the treatment of (acute) myocardial infarction |
| EP1985697A1 (en) | 2007-04-27 | 2008-10-29 | AM-Pharma B.V. | Modified phosphatases |
| HUE031655T2 (hu) * | 2007-05-11 | 2017-07-28 | Alexion Pharma Inc | Csontot targetáló alkálikus foszfatáz, készletek és eljárások alkalmazásukra |
| EP2030980A1 (en) | 2007-08-28 | 2009-03-04 | AM-Pharma B.V. | Mutants of lactoferrin |
| WO2009106368A1 (en) | 2008-02-29 | 2009-09-03 | Gelato Corporation N.V. | Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases |
| JP2011521916A (ja) | 2008-05-19 | 2011-07-28 | バーナム インスティテュート フォー メディカル リサーチ | 腸アルカリホスファターゼモジュレーターおよびそれの使用 |
| WO2010025267A2 (en) | 2008-08-29 | 2010-03-04 | The General Hospital Corporation | Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase |
| BR112012027765A2 (pt) * | 2010-04-30 | 2019-09-24 | Enobia Pharma Inc. | métodos, composições e kits para tratamento de distúrbios de mineralização da matriz. |
| EP3222286B1 (en) | 2011-06-08 | 2020-10-21 | AM-Pharma B.V. | The use of alkaline phosphatase for preserving renal function |
| ES2810813T3 (es) | 2014-01-24 | 2021-03-09 | Am Pharma Bv | Procesamiento para recuperación y purificación de una fosfatasa alcalina |
| CA2937328C (en) | 2014-01-24 | 2022-09-27 | Am-Pharma B.V. | Chimeric alkaline phosphatase-like proteins |
-
2015
- 2015-01-26 CA CA2937328A patent/CA2937328C/en active Active
- 2015-01-26 PE PE2016001271A patent/PE20161442A1/es unknown
- 2015-01-26 CN CN201580016357.1A patent/CN106164262B/zh active Active
- 2015-01-26 EP EP15703642.7A patent/EP3097189B1/en active Active
- 2015-01-26 DK DK15703642.7T patent/DK3097189T3/da active
- 2015-01-26 ES ES15703642.7T patent/ES2684639T3/es active Active
- 2015-01-26 EP EP18174759.3A patent/EP3425048A1/en not_active Withdrawn
- 2015-01-26 MX MX2016009625A patent/MX369041B/es active IP Right Grant
- 2015-01-26 WO PCT/NL2015/050048 patent/WO2015112017A1/en not_active Ceased
- 2015-01-26 SG SG11201606060WA patent/SG11201606060WA/en unknown
- 2015-01-26 AU AU2015209783A patent/AU2015209783B2/en active Active
- 2015-01-26 HU HUE15703642A patent/HUE039784T2/hu unknown
- 2015-01-26 RU RU2016131879A patent/RU2683635C2/ru active
- 2015-01-26 SI SI201530345T patent/SI3097189T1/sl unknown
- 2015-01-26 BR BR112016017041-5A patent/BR112016017041B1/pt active IP Right Grant
- 2015-01-26 PL PL15703642T patent/PL3097189T3/pl unknown
- 2015-01-26 PH PH1/2016/501441A patent/PH12016501441B1/en unknown
- 2015-01-26 KR KR1020167022726A patent/KR102166110B1/ko active Active
- 2015-01-26 US US15/113,696 patent/US9926544B2/en active Active
- 2015-01-26 CN CN202010673719.7A patent/CN111778228A/zh active Pending
- 2015-01-26 JP JP2016548124A patent/JP6940949B2/ja active Active
-
2016
- 2016-07-19 ZA ZA2016/05028A patent/ZA201605028B/en unknown
- 2016-07-21 SA SA516371532A patent/SA516371532B1/ar unknown
- 2016-07-21 IL IL246898A patent/IL246898B/en active IP Right Grant
-
2018
- 2018-02-07 US US15/891,208 patent/US10822597B2/en active Active
-
2019
- 2019-12-20 JP JP2019230887A patent/JP2020058375A/ja active Pending
-
2020
- 2020-10-16 US US17/072,893 patent/US11746340B2/en active Active
-
2022
- 2022-07-22 JP JP2022117484A patent/JP7408734B2/ja active Active
-
2023
- 2023-05-30 US US18/325,714 patent/US12534713B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12534713B2 (en) | Chimeric alkaline phosphatase-like proteins | |
| Millán et al. | Alkaline phosphatase and hypophosphatasia | |
| EP2155866B1 (en) | Modified phosphatases | |
| US20150352131A1 (en) | Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis | |
| EP2976094B1 (en) | Methods of treating metabolic disorders | |
| WO2017216165A1 (en) | Compositions and methods for the treatment or prevention of oxalate-related disorders | |
| HK1227925A1 (en) | Chimeric alkaline phosphatase-like proteins | |
| HK1227925B (en) | Chimeric alkaline phosphatase-like proteins | |
| NZ722253B2 (en) | Chimeric alkaline phosphatase-like proteins | |
| Huggins | The Involvement of P2X7R Signalling in LOX Mediated Formation of a Pre-Metastatic Niche in Bone |